Chronic Obstructive Pulmonary Disease (COPD)

Table of Contents

1. What is COPD?
2. What Actually Goes Wrong
3. Types of COPD
4. Symptoms of COPD
5. How It Varies Between People
6. Risk Factors
7. Diagnosis: The Tests and the Numbers
8. Staging and the ABE Groups
9. Treatment Options
10. Oxygen, Ventilation and Surgery
11. Exacerbations: What to Do
12. What the Evidence Does Not Support
13. Prevention Strategies
14. Practical Detail: Costs, Nutrition, Daily Life
15. Red Flags: When It Is Urgent
16. Complications of COPD
17. Research Papers
18. Connections
19. Featured Videos

What is COPD?

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition in which airflow out of the lungs is permanently limited, caused by damage to the small airways, the air sacs, or both. Unlike asthma, the obstruction does not fully reverse with a bronchodilator — though it usually improves, and that improvement is what treatment buys.

A picture that helps: healthy lung tissue behaves like a fresh sponge with elastic recoil. Squeeze it and it springs back, pushing air out. In emphysema, the walls between the air sacs are destroyed, so instead of 300 million small elastic sacs you have a smaller number of large floppy ones. The sponge has lost its spring. Air goes in easily enough but has to be pushed out, and because the small airways are no longer held open by the surrounding tissue, they collapse during exhalation and trap air behind them.

That trapped air is the reason COPD feels the way it does. The lungs become progressively over-inflated — hyperinflation — so the diaphragm is pushed flat and loses mechanical advantage, and each breath starts from a chest that is already partly full. This is why breathlessness in COPD is often described as “I can’t get a full breath in” rather than “I can’t get air out”, even though the underlying problem is expiratory. It is also why bronchodilators help people feel dramatically better while barely changing FEV₁: they reduce trapped volume, letting the chest start each breath from a better position.

COPD is the third leading cause of death worldwide, and it is substantially under-diagnosed — a large fraction of people with airflow obstruction on spirometry have never been told they have it.

What Actually Goes Wrong

Inhaled particles — tobacco smoke above all, but also biomass smoke, dusts and fumes — provoke a chronic inflammatory response in the airways dominated by neutrophils, macrophages and CD8 T cells. Three consequences follow:

1. Protease–antiprotease imbalance. Inflammatory cells release elastase, an enzyme that digests elastin. Normally alpha-1 antitrypsin neutralises it. Smoking both increases elastase release and chemically inactivates alpha-1 antitrypsin, so the lung digests its own scaffolding. This is the direct mechanism of emphysema, and it is exactly why people born with alpha-1 antitrypsin deficiency develop emphysema young, sometimes without ever smoking.
2. Small-airway remodelling. The bronchioles under 2 mm across become inflamed, fibrosed and narrowed, and many are obliterated entirely. Imaging studies suggest a substantial proportion of the small airways are lost before emphysema becomes visible — damage is well advanced before spirometry looks abnormal.
3. Mucus hypersecretion and impaired clearance. Goblet cells multiply, cilia are damaged and shortened, and mucus sits still. That is chronic bronchitis, and it is also why bacterial colonisation and repeated infection are so characteristic.

Two facts follow that patients are rarely told. First, some airflow decline continues even after stopping smoking — but the rate of decline returns close to normal, which is why quitting at any stage still changes the trajectory. The Lung Health Study (Anthonisen et al., Am J Respir Crit Care Med 2002) followed participants for 11 years and found sustained quitters had a markedly slower FEV₁ decline than continuing smokers. Second, COPD is a systemic disease as well as a lung disease: muscle wasting, osteoporosis, cardiovascular disease and depression are part of the illness, not incidental.

Types of COPD

The old division into two “types” is a simplification — most people have both to some degree — but it remains clinically useful because the dominant pattern predicts which problems you will face.

1. Chronic bronchitis

• Definition: a productive cough on most days for at least three months a year, in two consecutive years.
• Dominant problems: sputum production, recurrent chest infections, more frequent exacerbations.
• Classic picture: more likely to retain carbon dioxide, more likely to develop right heart strain, more likely to be overweight rather than underweight.

2. Emphysema

• Definition: permanent destruction of the alveolar walls distal to the terminal bronchioles.
• Dominant problems: breathlessness on exertion, hyperinflation, low diffusing capacity, weight loss.
• Classic picture: thin, barrel-chested, breathing through pursed lips — which is a genuinely effective self-taught manoeuvre, because it raises airway pressure and stops the small airways collapsing on exhalation.

3. Overlaps worth naming

• Asthma–COPD overlap — fixed obstruction with prominent eosinophilic inflammation and marked bronchodilator response. This group needs an inhaled corticosteroid, which most COPD does not.
• Alpha-1 antitrypsin deficiency — a genetic cause, typically lower-lobe emphysema, often diagnosed 20 years earlier than usual COPD. Every person with COPD should be tested for it once. It is inexpensive, and it changes management and family screening.
• Bronchiectasis–COPD overlap — permanently dilated, chronically infected airways alongside COPD. Suspect it with daily large-volume sputum and frequent infections; it is diagnosed on CT and changes antibiotic strategy.

Symptoms of COPD

• Breathlessness on exertion, gradually progressive over years. Typically the first symptom people actually notice, and typically attributed to age or being unfit until it is well advanced.
• Chronic cough, often the earliest symptom, frequently dismissed as a “smoker’s cough”.
• Sputum production, usually clear or white; a change to yellow or green with increased volume suggests an exacerbation.
• Wheeze and chest tightness, more variable than in asthma.
• Frequent or slow-to-clear chest infections.
• Fatigue and unintentional weight loss in advanced disease — the work of breathing itself burns substantial calories.
• Ankle swelling, which suggests right-sided heart strain (cor pulmonale) and is a marker of advanced disease.

How It Varies Between People

• Exacerbation frequency is a stable trait. Some people have two or more exacerbations a year at a given lung function while others of identical FEV₁ have none. Past exacerbation history is the best predictor of future exacerbations — better than spirometry — and it drives treatment choice.
• Symptoms track lung function poorly. Someone with an FEV₁ of 45% predicted may walk a mile; another at 65% may be housebound. Treat the person, not the number.
• Eosinophil count predicts steroid response. A blood eosinophil count above roughly 300 cells/µL identifies people who benefit from an inhaled corticosteroid; below 100 cells/µL, the steroid mostly adds pneumonia risk. This single cheap blood test is one of the most consequential in COPD care.
• Never-smokers get COPD too — roughly a quarter of cases worldwide, driven by biomass smoke, occupational exposure, childhood respiratory illness, and impaired lung growth in early life. Being a never-smoker does not exclude the diagnosis.
• Women appear more susceptible to smoke-related lung damage at equivalent exposure, and are more likely to have the breathless, emphysematous phenotype.

Risk Factors

• Tobacco smoking — the dominant cause in high-income countries. Risk is dose-dependent, but only a minority of smokers develop clinically significant COPD, which tells you susceptibility varies.
• Biomass fuel smoke — cooking and heating with wood, dung or coal indoors. Globally this is a major cause, and it disproportionately affects women.
• Occupational dusts, vapours and fumes — coal, silica, cadmium, welding fume, grain dust. Occupational exposure is estimated to account for around 15% of cases.
• Alpha-1 antitrypsin deficiency — the one clearly established genetic cause, though other genetic influences on susceptibility are well documented.
• Impaired lung growth — prematurity, childhood asthma, severe childhood respiratory infection, and maternal smoking all reduce peak lung function reached in early adulthood. Starting lower means reaching the disease threshold sooner even with a normal rate of decline.
• Outdoor air pollution, especially long-term fine particulate exposure.
• Untreated asthma and repeated severe exacerbations of it.

Diagnosis: The Tests and the Numbers

Spirometry — required, not optional

COPD cannot be diagnosed on symptoms and a chest X-ray. It requires post-bronchodilator spirometry showing a persistent FEV₁/FVC ratio below 0.70 (or, more accurately, below the lower limit of normal for your age, sex and height). The measurement must be taken after inhaling a bronchodilator, because pre-bronchodilator readings over-diagnose the condition. If you have been told you have COPD and have never blown into a spirometer, ask for one.

The GOLD grades are based on FEV₁ as a percentage of predicted, in people who already meet the ratio criterion:

• GOLD 1 (mild) — FEV₁ 80% predicted or above.
• GOLD 2 (moderate) — 50–79%.
• GOLD 3 (severe) — 30–49%.
• GOLD 4 (very severe) — below 30%.

Other tests, and what each adds

• Full blood count — for the eosinophil count (guides inhaled steroid use) and to detect the secondary polycythaemia of chronic hypoxaemia or, conversely, anaemia as a treatable cause of breathlessness.
• Alpha-1 antitrypsin level — once, in everyone with COPD. A level below about 20 µmol/L (roughly 80 mg/dL) warrants genotyping.
• Pulse oximetry — a resting saturation of 92% or less prompts arterial or capillary blood gas measurement to assess for long-term oxygen therapy.
• Chest CT — quantifies emphysema, finds bronchiectasis, and is required before any surgical or valve procedure. Low-dose CT screening for lung cancer is separately indicated in most people with a smoking history and COPD.
• Diffusing capacity (DLCO) — low in emphysema, normal in pure chronic bronchitis. It also helps separate COPD from other causes of breathlessness.
• Echocardiogram — where cor pulmonale or coexisting heart failure is suspected. Breathlessness in an older smoker is very often both lungs and heart.
• Six-minute walk test — a practical functional measure and part of the BODE prognostic index (Body mass index, Obstruction, Dyspnoea, Exercise capacity), which predicts survival better than FEV₁ alone.

Staging and the ABE Groups

Modern GOLD guidance separates how obstructed you are (the numerical grade above) from how you are doing, because the second drives treatment. Symptoms are scored with the mMRC breathlessness scale or the CAT questionnaire, and exacerbation history over the past year is added:

• Group A — few symptoms, 0–1 moderate exacerbations, no hospitalisation.
• Group B — more symptoms, 0–1 moderate exacerbations, no hospitalisation.
• Group E — two or more moderate exacerbations, or any exacerbation needing hospital admission, regardless of symptom burden.

The mMRC scale is worth knowing because you will be asked: 0 = breathless only on strenuous exercise; 1 = short of breath hurrying or walking up a slight hill; 2 = walks slower than people of the same age, or has to stop for breath walking on the level; 3 = stops for breath after about 100 metres; 4 = too breathless to leave the house or breathless dressing.

Treatment Options

The two interventions that change survival

Almost everything in COPD improves symptoms. Only three things have been shown to prolong life: stopping smoking, long-term oxygen therapy in those who are chronically hypoxaemic, and lung volume reduction surgery in a carefully selected subgroup. Everything else is about breathlessness, exacerbations and quality of life — which matter enormously, but should be described honestly.

Inhaled bronchodilators

• Long-acting muscarinic antagonists (LAMA) — tiotropium, glycopyrronium, umeclidinium, aclidinium. The UPLIFT trial (Tashkin et al., NEJM 2008) followed nearly 6,000 people for four years: tiotropium improved lung function, quality of life and exacerbation rate but did not slow the rate of FEV₁ decline, which was the primary hypothesis. That honest negative on disease modification sits alongside genuine symptomatic benefit.
• Long-acting beta-2 agonists (LABA) — formoterol, salmeterol, indacaterol, vilanterol, olodaterol.
• LAMA + LABA combination — more effective than either alone. In FLAME (Wedzicha et al., NEJM 2016), indacaterol–glycopyrronium was superior to salmeterol–fluticasone at preventing exacerbations, with less pneumonia. This trial is a major reason dual bronchodilation, not a steroid combination, is now the default for most COPD.
• Short-acting relievers — salbutamol, ipratropium, for as-needed use.

Inhaled corticosteroids — for a specific subgroup, not everyone

Inhaled steroids in COPD have real benefits in the right person and real harms in the wrong one. TORCH (Calverley et al., NEJM 2007) tested salmeterol–fluticasone against placebo for three years: mortality fell from 15.2% to 12.6%, but the difference did not reach the pre-specified threshold for statistical significance, so the headline result is not a proven mortality benefit — while pneumonia was clearly increased in the steroid arms.

Later trials refined who benefits. IMPACT (Lipson et al., NEJM 2018) and ETHOS (Rabe et al., NEJM 2020) both found single-inhaler triple therapy (ICS + LAMA + LABA) reduced exacerbations compared with dual therapy, with the benefit concentrated in people with higher blood eosinophil counts and a history of exacerbations — and with a consistent excess of pneumonia. The practical rule that emerged:

• Eosinophils above 300 cells/µL with exacerbations — add an inhaled steroid.
• Eosinophils 100–300 cells/µL with repeated exacerbations — consider it.
• Eosinophils below 100 cells/µL — unlikely to help, and pneumonia risk still applies.

Other drug options

• Roflumilast — an oral PDE4 inhibitor for severe COPD with chronic bronchitis and frequent exacerbations. REACT (Martinez et al., Lancet 2015) showed a reduction in exacerbations on top of inhaled therapy. Diarrhoea, nausea, weight loss and mood disturbance limit its use in practice; warn people about the weight loss.
• Azithromycin — 250 mg daily or 500 mg three times weekly for a year reduced exacerbations in Albert et al. (NEJM 2011). The trade-offs are explicit: a small but measurable hearing decrement, QT prolongation, and the promotion of macrolide resistance. Reserve it for frequent exacerbators, check an ECG and hearing first, and review the decision annually.
• Dupilumab — the first biologic with proven benefit in COPD. In BOREAS (Bhatt et al., NEJM 2023), dupilumab reduced moderate or severe exacerbations by around 30% in people with type 2 inflammation defined by blood eosinophils of 300 cells/µL or more, already on triple therapy.
• Mucolytics — carbocisteine or N-acetylcysteine modestly reduce exacerbations in chronic bronchitis, particularly in people not taking an inhaled steroid.
• Vaccination — annual influenza, pneumococcal, RSV in older adults, and pertussis-containing boosters. Influenza vaccination reduces exacerbations and hospitalisation in COPD; this is among the best-evidenced simple interventions available.

Pulmonary rehabilitation — the most under-used effective treatment

A supervised programme of exercise training, education and self-management, typically twice weekly for 6–12 weeks. It improves exercise capacity and quality of life more than any drug, and rehabilitation started shortly after a hospitalised exacerbation reduces readmission. Uptake is poor, largely because it is not offered. Ask for a referral by name.

Oxygen, Ventilation and Surgery

• Long-term oxygen therapy (LTOT) — for people with a resting arterial oxygen tension at or below 55 mmHg (7.3 kPa), or at or below 59 mmHg (7.9 kPa) with cor pulmonale or polycythaemia. It must be used at least 15 hours a day to prolong survival; the landmark Nocturnal Oxygen Therapy Trial (Ann Intern Med 1980) showed continuous oxygen was superior to nocturnal-only. Oxygen is not a treatment for breathlessness. In people who are not hypoxaemic it does not improve symptoms or survival, and it carries a real fire risk.
• Home non-invasive ventilation — for chronic hypercapnia, particularly persistent carbon dioxide retention after a hospital admission. High-intensity NIV in this group reduces readmission and mortality.
• Lung volume reduction — the NETT trial (Fishman et al., NEJM 2003) found surgery improved survival specifically in people with upper-lobe-predominant emphysema and low baseline exercise capacity, and increased mortality in those with very low FEV₁ and homogeneous emphysema. Selection is everything. Endobronchial valves, placed at bronchoscopy, now offer a less invasive option for suitable people with little collateral ventilation.
• Lung transplantation — for very severe disease in otherwise suitable candidates; it improves quality of life, with a more debated effect on survival.

Exacerbations: What to Do

An exacerbation is a sustained worsening of breathlessness, cough or sputum beyond normal day-to-day variation. They matter more than almost anything else: each one accelerates lung-function decline, and hospitalisation for one carries a substantial one-year mortality.

• Increase the short-acting bronchodilator, using a spacer.
• Oral corticosteroids — prednisolone 40 mg daily for 5 days is the standard course for a moderate or severe exacerbation. Five days is as good as fourteen, and no taper is needed.
• Antibiotics — indicated when sputum becomes purulent and increases in volume, or when ventilation is required. Purulence is the useful discriminator; not every exacerbation is bacterial.
• A written self-management plan with a rescue pack — a course of steroids and antibiotics kept at home with clear instructions on when to start them — reduces time to treatment. It works only alongside education about when not to use it; unsupervised rescue packs used for every symptom cause harm.
• Controlled oxygen in hospital — target saturation 88–92% in known or suspected COPD, not 94–98%. Excess oxygen in a carbon-dioxide retainer worsens hypercapnia and has been shown to increase mortality in the pre-hospital setting.

What the Evidence Does Not Support

• Inhaled steroids for everyone with COPD. In people with low eosinophil counts they increase pneumonia risk without preventing exacerbations. Withdrawal of an inhaled steroid in low-eosinophil patients on adequate dual bronchodilation is generally safe.
• Oxygen for breathlessness without hypoxaemia. Trials in people with moderate resting or exercise desaturation found no benefit in survival, hospitalisation, quality of life or walking distance.
• Tiotropium as a disease-modifying drug. UPLIFT was explicitly designed to test whether it slows FEV₁ decline. It does not. It remains a good symptomatic and exacerbation-reducing treatment.
• Antitussives to suppress the cough. Cough clears sputum in COPD; suppressing it is not recommended.
• Routine long-term prophylactic antibiotics in everyone. The benefit shown for azithromycin applies to frequent exacerbators; applied broadly it drives resistance for little gain.
• Antioxidant vitamin supplements as treatment. Despite a coherent oxidative-stress rationale, vitamin supplementation has not been shown to alter COPD progression or exacerbation rates. Adequate nutrition matters; high-dose supplements have not delivered.

Prevention Strategies

• Stop smoking. This is the only intervention that changes the rate of lung-function decline. Combining pharmacotherapy (varenicline, nicotine replacement, bupropion) with behavioural support roughly triples quit rates compared with willpower alone. It is worth doing at every stage, including in advanced disease.
• Reduce indoor biomass smoke — improved stoves and ventilation where solid fuel is used for cooking or heating.
• Occupational protection — respiratory protective equipment, exposure limits, and health surveillance in dusty trades.
• Vaccinate — annually against influenza, plus pneumococcal, RSV and pertussis as advised.
• Treat asthma properly in childhood and adulthood, and protect children from secondhand smoke, to preserve peak lung function.
• Ask for spirometry if you are over 40 with a smoking history and any cough or breathlessness. Early diagnosis is worth having because it is the point at which quitting changes the most.

Practical Detail: Costs, Nutrition, Daily Life

• Inhaler devices matter more than brands. Someone with weak inspiratory flow — common in severe COPD — cannot use a dry-powder inhaler effectively and needs a metered-dose inhaler with a spacer, or a soft-mist device. If a new inhaler seems to have stopped working, suspect the device before the drug.
• Costs. Generic tiotropium and generic LABA/ICS combinations have brought prices down considerably. In the United States, several manufacturers have capped monthly out-of-pocket inhaler costs since 2024; ask the pharmacist to price the same molecule in a different device, since the difference can be large. Pulmonary rehabilitation is usually covered by insurance and by the NHS, and is among the cheapest high-value interventions available.
• Nutrition. Both underweight and obesity worsen outcomes. In advanced emphysema, unintentional weight loss and muscle wasting predict mortality independently of lung function; small frequent meals, adequate protein and, where needed, supplementation help. Practical protein sources include eggs, fish such as salmon and sardines, poultry, meat, lentils, beans, nuts, whole-milk dairy and Greek yogurt. Build meals around vegetables, fruit, olive oil, nuts and whole grains — brown rice, oats, barley and buckwheat. Large carbohydrate-heavy meals can transiently increase carbon dioxide production and worsen breathlessness in people who retain CO₂, which is a further argument for smaller, more frequent meals.
• Breathing techniques. Pursed-lip breathing on exhalation and forward-leaning positions with the arms supported both reduce breathlessness measurably and cost nothing.
• Handheld fan. A stream of cool air directed at the face reduces the sensation of breathlessness through trigeminal nerve stimulation. It is trivially cheap and genuinely evidence-supported.
• What to ask for by name: post-bronchodilator spirometry with the actual numbers; a blood eosinophil count; a one-off alpha-1 antitrypsin level; referral to pulmonary rehabilitation; a written self-management plan; an inhaler technique check; assessment for long-term oxygen if your saturation is 92% or below; and, if you smoke or used to, low-dose CT lung cancer screening.

Red Flags: When It Is Urgent

• Breathlessness at rest, or unable to speak in sentences.
• Oxygen saturation falling below your usual baseline, particularly below 88%.
• New confusion, drowsiness, or a flapping tremor of the outstretched hands — these suggest carbon dioxide retention and are an emergency.
• Chest pain, which may indicate pneumonia, pulmonary embolism, pneumothorax or a cardiac event — all of which are commoner in COPD.
• Coughing blood. Never attribute haemoptysis to COPD itself without investigation; lung cancer risk is substantially raised.
• Sudden severe breathlessness with one-sided chest pain — consider pneumothorax, to which emphysematous lungs are prone.
• Rapidly worsening ankle swelling with breathlessness.

Interactions and cautions

• Uncontrolled oxygen in a CO₂ retainer — the single most important prescribing hazard in COPD. Ambulance and hospital staff should be told you have COPD so a 88–92% target is used.
• Benzodiazepines and opioids depress respiratory drive. Low-dose oral morphine is nonetheless an appropriate and evidence-supported treatment for refractory breathlessness in advanced disease, prescribed carefully.
• Azithromycin with other QT-prolonging drugs; check an ECG before starting long-term use.
• Beta-blockers are usually safe and often beneficial in COPD with cardiovascular disease. Cardioselective agents should not be withheld out of reflex caution — withholding them causes measurable harm.
• Roflumilast with weight loss or depression, both of which are recognised adverse effects.

Complications of COPD

• Respiratory failure — type 1 (low oxygen) and type 2 (low oxygen with high carbon dioxide).
• Cor pulmonale — right-heart failure from pulmonary hypertension caused by chronic hypoxaemia and loss of the pulmonary vascular bed.
• Pneumonia, and a further increase in risk with inhaled corticosteroid use.
• Pneumothorax from rupture of emphysematous bullae.
• Lung cancer — COPD raises risk independently of smoking, which is why CT screening is particularly worthwhile in this group.
• Cardiovascular disease — ischaemic heart disease, heart failure and arrhythmia are all commoner, and are a leading cause of death in mild-to-moderate COPD.
• Osteoporosis, from inactivity, low body weight, smoking and steroid exposure.
• Skeletal muscle dysfunction and sarcopenia, which is partly reversible with pulmonary rehabilitation.
• Anxiety and depression, present in a large minority and strongly associated with readmission.
• Obstructive sleep apnoea overlap — the combination causes more severe nocturnal hypoxaemia than either alone.

Back to Table of Contents

Research Papers

Historical background

Emphysema was described anatomically by Giovanni Battista Morgagni in 1769 and illustrated in detail by Matthew Baillie in 1789; René Laennec, inventor of the stethoscope, gave a clear clinical account in 1821. The link between smoking and chronic lung damage was established alongside the smoking–lung cancer work of the 1950s and 1960s, and Charles Fletcher and Richard Peto’s eight-year study of London working men, published in 1977, produced the famous curve showing that stopping smoking does not restore lost lung function but returns the rate of decline towards normal. That single observation still underpins the central message of COPD care.

Key research papers

Each citation below was checked against its PubMed record; the linked DOI resolves to the paper named.

1. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242. (PMID 35533707)
2. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. (PMID 22878278)
3. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. (PMID 28128970)
4. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675–679. (PMID 12204864)
5. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH). N Engl J Med. 2007;356(8):775–789. (PMID 17314337) — the mortality difference did not reach statistical significance.
6. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT). N Engl J Med. 2008;359(15):1543–1554. (PMID 18836213) — no effect on the rate of FEV₁ decline.
7. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. (PMID 21864166)
8. Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT). Lancet. 2015;385(9971):857–866. (PMID 25684586)
9. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD (FLAME). N Engl J Med. 2016;374(23):2222–2234. (PMID 27181606)
10. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD (IMPACT). N Engl J Med. 2018;378(18):1671–1680. (PMID 29668352)
11. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD (ETHOS). N Engl J Med. 2020;383(1):35–48. (PMID 32579807)
12. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts (BOREAS). N Engl J Med. 2023;389(3):205–214. (PMID 37272521)
13. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391–398. (PMID 6776858)
14. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema (NETT). N Engl J Med. 2003;348(21):2059–2073. (PMID 12759479)

Live PubMed searches

The following PubMed topic searches surface the current peer-reviewed literature on COPD. Each link opens a live query; results update as new papers are indexed.

1. PubMed search: chronic obstructive pulmonary disease
2. PubMed search: COPD GOLD guidelines
3. PubMed search: COPD exacerbation
4. PubMed search: COPD blood eosinophil inhaled corticosteroid
5. PubMed search: emphysema
6. PubMed search: chronic bronchitis
7. PubMed search: pulmonary rehabilitation
8. PubMed search: alpha 1 antitrypsin deficiency
9. PubMed search: COPD smoking cessation
10. PubMed search: long term oxygen therapy COPD
11. PubMed search: endobronchial valve emphysema
12. PubMed search: lung volume reduction surgery
13. PubMed search: COPD non invasive ventilation hypercapnia
14. PubMed search: COPD cardiovascular comorbidity

Back to Table of Contents

Connections

• Pulmonology
• Asthma: What Happens in an Attack — interactive animation
• Surfactant: Why Your Lungs Don’t Collapse — interactive animation
• Hemoglobin & the Oxygen Dissociation Curve — interactive animation
• Blood pH: The Acid–Base Balancing Act — interactive animation
• Breathing & Gas Exchange — interactive animation
• Pneumonia
• Shortness of Breath
• Chronic Cough
• Asthma
• Pulmonary Hypertension
• Vitamin D3
• Eucalyptus
• Breathwork
• Interstitial Lung Disease
• Obstructive Sleep Apnea
• Pulmonary Embolism
• Fatigue
• Depression
• Lead Toxicity
• Magnesium
• Hypertension
• Chest Pain
• Cancer
• Mullein
• Lung Cancer
• RSV
• Herbs covered on this site that discuss this condition: Elecampane · Boswellia · Horehound · Savory · White Turmeric / Zedoary (Curcuma zedoaria)
• Influenza — a common trigger of exacerbations, and why annual vaccination is part of COPD care

Back to Table of Contents

×

Featured Videos